Literature DB >> 21152788

Photodynamic therapy with delta-aminolevulinic acid and light-emitting diodes in actinic keratosis.

Clarice Gabardo Ritter1, Isabel Cristina Palma Kuhl, Carolina Lenhardt, Marlene Laks Weissbluth, Renato Marchiori Bakos.   

Abstract

BACKGROUND: Photodynamic therapy is a form of treatment in which a photosensitizing substance is applied to tissue and activated by a light source at a specific wavelength, thus selectively destroying cells. New light sources are being evaluated for use in the treatment of actinic keratoses.
OBJECTIVES: To evaluate the efficacy of photodynamic therapy with delta-aminolevulinic acid using a light emitting diode device as a light source in the treatment of actinic keratoses of the face and upper limbs.
METHODS: Eighteen patients with actinic keratoses of the face or upper limbs received an application of a 20% delta-aminolevulinic acid cream and were submitted to diode light irradiation at a wavelength of 630 nm.
RESULTS: A total of 328 actinic keratoses were treated, obtaining complete cure in 210 (64.0%) after 24 weeks. Lesions situated on the back of the hands were clinically cured in 49.2% of cases compared to 81.4% in the cases of lesions in other areas. There was no record of any severe adverse effects and patient satisfaction with the results was high.
CONCLUSION: Photodynamic therapy with a diode light emitting source proved effective and well-tolerated for the treatment of actinic keratoses, with results similar to those reported in the literature with other light sources.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21152788     DOI: 10.1590/s0365-05962010000500007

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  1 in total

1.  Topical Photodynamic Therapy with Different Forms of 5-Aminolevulinic Acid in the Treatment of Actinic Keratosis.

Authors:  Joanna Bartosińska; Paulina Szczepanik-Kułak; Dorota Raczkiewicz; Marta Niewiedzioł; Agnieszka Gerkowicz; Dorota Kowalczuk; Mirosław Kwaśny; Dorota Krasowska
Journal:  Pharmaceutics       Date:  2022-02-01       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.